Analyst consensus rating
CytoMed Therapeutics Analyst Rating: Strong Buy
Direct answer
CytoMed Therapeutics's consensus rating is Strong Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.16.
Forecast evidence checked September 21, 2026.
Get free CytoMed Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.98
- Average price target
- $4.16
- High price target
- $4.16
- Low price target
- $4.16
- Low target gap
- +324.5%
- Target upside
- +324.5%
- High target gap
- +324.5%
- Target range width
- 0%
- Consensus rating
- Strong Buy
- Analysts
- 1
- Evidence date
- September 21, 2026
- Valid through
- September 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CytoMed Therapeutics?
CytoMed Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $4.16.
How far are CytoMed Therapeutics's low and high targets from the recorded price?
The low target implies +324.5%, while the high target implies +324.5%.
How many analysts are included in CytoMed Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is CytoMed Therapeutics's target upside or downside calculated?
The average target of $4.16 is divided by the recorded price of $0.98, then one is subtracted to produce +324.5%. This does not guarantee a future return.
When was CytoMed Therapeutics's analyst forecast verified?
The data was verified on 2026-09-21. The dataset is valid through 2026-09-28.